logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Inclisiran for primary hypercholesterolaemia and mixed dyslipidaemia

< Back

Inclisiran for primary hypercholesterolaemia and mixed dyslipidaemia

Drugs

Endocrine, Nutritional and Metabolic

May 2019


Inclisiran is in clinical development for treatment of hypercholesterolaemia in patients at high risk of cardiovascular disease in addition to, or after use of, oral anti‐lipidaemics
including statins. Abnormal levels of lipids in the blood characterises dyslipidaemia. High levels of cholesterol in the blood (hypercholesterolemia) may be caused by inherited genetic
defects as seen in familial hypercholesterolaemia, or may occur when genes and other factors such as lifestyle habits interact, as seen in non‐familial hypercholesterolaemia.
Elevated levels of low‐density lipoprotein cholesterol (LDL‐C) increase the risk of cardiovascular disease, which is responsible for many deaths and disabilities.
The current standard of care for patients with hypercholesterolaemia is primarily statins which are capable of reducing LDL‐C. There is however a subset of patients who are unable
to reach LDL‐C goals despite maximally tolerated oral lipid lowering therapy. Inclisiran is a medicinal product that inhibits a protein called PCSK9 especially present on the liver cells
leading to a decrease in circulating LDL‐C. If licensed, inclisiran will offer an additional treatment option for patients with primary hypercholesterolaemia as adjunctive therapy to diet and in combination with other lipid‐lowering therapies.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts